Poliklinika Borzan d.o.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
The site concentrates on inflammatory bowel disease research, investigating both Crohn’s disease and ulcerative colitis, as well as celiac disease in patients with persistent symptoms.
- Evaluation of novel biologic agents for induction and maintenance therapy
- Oral small‑molecule treatments targeting gut inflammation
- Biosimilar comparison studies to improve access
- Combination regimens that integrate immunomodulators
- Long‑term safety and tolerability assessments
Poliklinika Borzan d.o.o. is currently running 29 trials led by three investigators, aiming to bring effective options to patients with moderate to severe gastrointestinal disorders.
Immune System Diseases
Clinical work at the clinic addresses immune‑mediated gastrointestinal disorders, focusing on therapies that modulate key cytokine pathways.
- Targeted therapies such as IL‑23 and IL‑12/23 inhibitors
- Cytokine blockade using monoclonal antibodies
- Mechanistic profiling to understand drug action
- Comparative studies of existing biologics versus new agents
- Evaluation of safety in patients naïve to biologic treatment
Ongoing studies include head‑to‑head trials of risankizumab versus vedolizumab, and investigations of combination strategies with upadacitinib.
Immune System Phenomena
Research also explores the underlying immune system phenomena that drive disease activity, aiming to personalize therapy.
- Therapeutic drug monitoring to guide dose adjustments
- Biomarker discovery for predicting response
- Immune phenotyping of patient sub‑groups
- Safety profiling of long‑term immunosuppression
- Evaluation of endoscopic and histologic endpoints
These efforts support the development of precision approaches, ensuring that patients receive the most appropriate treatment based on their individual immune profile.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Poliklinika Borzan d.o.o.
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Participants Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study in Participants with Moderate-to-Severe Active Ulcerative Colitis. | Xencor Inc. | Phase II | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Risankizumab | 4 | Unknown | 2017-11-08 | 2025-07-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.